These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23828223)

  • 1. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
    Kutlar A; Reid ME; Inati A; Taher AT; Abboud MR; El-Beshlawy A; Buchanan GR; Smith H; Ataga KI; Perrine SP; Ghalie RG
    Am J Hematol; 2013 Nov; 88(11):E255-60. PubMed ID: 23828223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
    Kutlar A; Ataga K; Reid M; Vichinsky EP; Neumayr L; Blair-Britt L; Labotka R; Glass J; Keefer JR; Wargin WA; Berenson R; Perrine SP
    Am J Hematol; 2012 Nov; 87(11):1017-21. PubMed ID: 22887019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
    Reid ME; El Beshlawy A; Inati A; Kutlar A; Abboud MR; Haynes J; Ward R; Sharon B; Taher AT; Smith W; Manwani D; Ghalie RG
    Am J Hematol; 2014 Jul; 89(7):709-13. PubMed ID: 24677033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
    Fucharoen S; Inati A; Siritanaratku N; Thein SL; Wargin WC; Koussa S; Taher A; Chaneim N; Boosalis M; Berenson R; Perrine SP
    Br J Haematol; 2013 May; 161(4):587-93. PubMed ID: 23530969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.
    Perrine SP; Wargin WA; Boosalis MS; Wallis WJ; Case S; Keefer JR; Faller DV; Welch WC; Berenson RJ
    J Clin Pharmacol; 2011 Aug; 51(8):1186-94. PubMed ID: 21422239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
    Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.
    Atweh GF; Sutton M; Nassif I; Boosalis V; Dover GJ; Wallenstein S; Wright E; McMahon L; Stamatoyannopoulos G; Faller DV; Perrine SP
    Blood; 1999 Mar; 93(6):1790-7. PubMed ID: 10068649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
    Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
    N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents.
    Knapp E; Cohen H; Kutlar A; Ghalie R; Manwani D
    Am J Hematol; 2016 Mar; 91(3):E11-2. PubMed ID: 26661045
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
    Papassotiriou I; Voskaridou E; Stamoulakatou A; Loukopoulos D
    Hematol J; 2000; 1(5):295-300. PubMed ID: 11920206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic reactivation of fetal haemoglobin.
    Olivieri NF; Weatherall DJ
    Hum Mol Genet; 1998; 7(10):1655-8. PubMed ID: 9735388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.
    Perrine SP; Olivieri NF; Faller DV; Vichinsky EP; Dover GJ; Ginder GD
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):67-71. PubMed ID: 7508690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
    Charache S; Dover GJ; Moore RD; Eckert S; Ballas SK; Koshy M; Milner PF; Orringer EP; Phillips G; Platt OS
    Blood; 1992 May; 79(10):2555-65. PubMed ID: 1375104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
    Atweh GF; Schechter AN
    Curr Opin Hematol; 2001 Mar; 8(2):123-30. PubMed ID: 11224687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.
    Inati A; Kahale M; Perrine SP; Chui DH; Taher AT; Koussa S; Abi Nasr T; Abbas HA; Ghalie RG
    Br J Haematol; 2014 Feb; 164(3):456-8. PubMed ID: 24224649
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
    Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
    Green NS; Ender KL; Pashankar F; Driscoll C; Giardina PJ; Mullen CA; Clark LN; Manwani D; Crotty J; Kisselev S; Neville KA; Hoppe C; Barral S
    PLoS One; 2013; 8(2):e55709. PubMed ID: 23409025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.